Solengepras shows promise in easing Parkinson's overlooked non-motor burden

This signals a growing focus on holistic Parkinson’s disease management.

Solengepras has shown early promise in addressing Parkinson’s disease’s (PD) overlooked non-motor burden, with Phase II data improving sleep and related symptoms despite limited motor gains.

According to GlobalData, this signals a growing focus on holistic disease management, where targeting non-motor pathways could redefine treatment priorities.

The randomised, placebo-controlled study assessed solengepras 150 milligrams once daily over 12 weeks in untreated early PD patients.

Whilst the primary motor endpoint (MDS-UPDRS Parts II and III) showed only modest improvement versus placebo (−0.73), more meaningful effects were observed across non-motor domains.

Solengepras improved MDS-UPDRS Part I scores (−1.01 at Week 12), with consistent benefits in sleep-related measures, including MDS-UPDRS sleep components and Epworth Sleepiness Scale scores.

Additional directional improvements were seen in autonomic symptoms and behaviour, whilst cognition and mood remained largely unchanged.

Non-motor symptoms such as sleep dysfunction, fatigue, and cognitive impairment are recognised as key drivers of disease burden in PD.

However, the current therapies, including levodopa and dopamine agonists, offer limited efficacy in these areas.